These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 23810242

  • 1. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.
    Press RD, Kamel-Reid S, Ang D.
    J Mol Diagn; 2013 Sep; 15(5):565-76. PubMed ID: 23810242
    [Abstract] [Full Text] [Related]

  • 2. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
    Arora R, Press RD.
    Leuk Lymphoma; 2017 Jan; 58(1):8-16. PubMed ID: 27412040
    [Abstract] [Full Text] [Related]

  • 3. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
    Elnair R, Galal A.
    BMC Cancer; 2018 Nov 12; 18(1):1097. PubMed ID: 30419862
    [Abstract] [Full Text] [Related]

  • 4. BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
    Luu MH, Press RD.
    Expert Rev Mol Diagn; 2013 Sep 12; 13(7):749-62. PubMed ID: 24063401
    [Abstract] [Full Text] [Related]

  • 5. Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation.
    Zhen C, Wang YL.
    J Mol Diagn; 2013 Sep 12; 15(5):556-64. PubMed ID: 23876601
    [Abstract] [Full Text] [Related]

  • 6. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G.
    Clin Lymphoma Myeloma Leuk; 2016 Aug 12; 16 Suppl():S96-S100. PubMed ID: 27131622
    [Abstract] [Full Text] [Related]

  • 7. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.
    Am J Hematol; 2012 Nov 12; 87(11):E125-8. PubMed ID: 23044928
    [Abstract] [Full Text] [Related]

  • 8. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2002 Sep 12; 16(9):1579-83. PubMed ID: 12200666
    [Abstract] [Full Text] [Related]

  • 9. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
    Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Müller MC, Radich JP, Shah NP.
    Leuk Res; 2014 Jan 12; 38(1):10-20. PubMed ID: 24131888
    [Abstract] [Full Text] [Related]

  • 10. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
    Beránek M, Voglová J, Sýkorová A, Belada D, Bláha M.
    Cas Lek Cesk; 2006 Jan 12; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
    [Abstract] [Full Text] [Related]

  • 11. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
    Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, Branford S, Hughes TP, Morley AA.
    Int J Lab Hematol; 2010 Dec 12; 32(6 Pt 1):e222-8. PubMed ID: 20491997
    [Abstract] [Full Text] [Related]

  • 12. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G, Iacobucci I, Soverini S, Cilloni D, Saglio G, Pane F, Baccarani M.
    Hematol Oncol; 2006 Dec 12; 24(4):196-204. PubMed ID: 16988930
    [Abstract] [Full Text] [Related]

  • 13. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR, Yang F, Press RD.
    Methods Mol Biol; 2013 Dec 12; 999():25-39. PubMed ID: 23666688
    [Abstract] [Full Text] [Related]

  • 14. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
    Mahon FX, Etienne G.
    Clin Cancer Res; 2014 Jan 15; 20(2):310-22. PubMed ID: 24166905
    [Abstract] [Full Text] [Related]

  • 15. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
    Baccarani M, Soverini S, De Benedittis C.
    Am Soc Clin Oncol Educ Book; 2014 Jan 15; ():167-75. PubMed ID: 24857074
    [Abstract] [Full Text] [Related]

  • 16. Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
    Koren-Michowitz M, Shimoni A, Daraio F, Crasto F, Lorenzatti R, Volchek Y, Amariglio N, Gottardi E, Saglio G, Nagler A.
    Biol Blood Marrow Transplant; 2015 Oct 15; 21(10):1852-5. PubMed ID: 26151304
    [Abstract] [Full Text] [Related]

  • 17. Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
    Shih LY, Kuo MC, Kuo CY, Lin TH, Bai LY, Chen TY, Wang MC, Lin TL, Lan YJ, Chen CC, Yang Y, Hsiao PC, Lai CL, Chang CH, Lin TH.
    Leuk Res; 2013 Jan 15; 37(1):43-9. PubMed ID: 23062378
    [Abstract] [Full Text] [Related]

  • 18. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
    Boeckx N, Laer CV, Roover JD, Wilmsen B, Bruyninckx K, Pauwels S.
    Acta Clin Belg; 2015 Aug 15; 70(4):237-43. PubMed ID: 26166681
    [Abstract] [Full Text] [Related]

  • 19. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group.
    Itonaga H, Tsushima H, Imanishi D, Hata T, Doi Y, Mori S, Sasaki D, Hasegawa H, Matsuo E, Nakashima J, Kato T, Horai M, Taguchi M, Matsuo M, Taniguchi H, Makiyama J, Sato S, Horio K, Ando K, Moriwaki Y, Sawayama Y, Ogawa D, Yamasaki R, Takasaki Y, Imaizumi Y, Taguchi J, Kawaguchi Y, Yoshida S, Joh T, Moriuchi Y, Nonaka H, Soda H, Fukushima T, Nagai K, Kamihira S, Tomonaga M, Yanagihara K, Miyazaki Y.
    Leuk Res; 2014 Jan 15; 38(1):76-83. PubMed ID: 24262285
    [Abstract] [Full Text] [Related]

  • 20. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
    Qin YZ, Jiang Q, Jiang H, Li JL, Li LD, Zhu HH, Lai YY, Lu XJ, Liu YR, Jiang B, Huang XJ.
    Leuk Res; 2013 Sep 15; 37(9):1035-40. PubMed ID: 23810191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.